116 related articles for article (PubMed ID: 34396926)
1. The clinical characteristics and prognostic value of IGFBP6 in glioma.
Zong Z; Xin L; Tang X; Guo H
Neurol Res; 2022 Feb; 44(2):113-120. PubMed ID: 34396926
[TBL] [Abstract][Full Text] [Related]
2. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
3. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
4. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
5. IGFBP6 Regulates Cell Apoptosis and Migration in Glioma.
Bei Y; Huang Q; Shen J; Shi J; Shen C; Xu P; Chang H; Xia X; Xu L; Ji B; Chen J
Cell Mol Neurobiol; 2017 Jul; 37(5):889-898. PubMed ID: 27650075
[TBL] [Abstract][Full Text] [Related]
6.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
8. RGS16 promotes glioma progression and serves as a prognostic factor.
Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
[TBL] [Abstract][Full Text] [Related]
9. IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker.
Chen Q; Qin S; Liu Y; Hong M; Qian CN; Keller ET; Zhang J; Lu Y
Oncotarget; 2016 Oct; 7(42):68140-68150. PubMed ID: 27623076
[TBL] [Abstract][Full Text] [Related]
10. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
11. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
12. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
14. Role of IGFBP6 Protein in the Regulation of Epithelial-Mesenchymal Transition Genes.
Nikulin SV; Raigorodskaya MP; Poloznikov AA; Zakharova GS; Schumacher U; Wicklein D; Stürken C; Riecken K; Fomicheva KA; Alekseev BY; Shkurnikov MY
Bull Exp Biol Med; 2018 Mar; 164(5):650-654. PubMed ID: 29577195
[TBL] [Abstract][Full Text] [Related]
15. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
16. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
17. Cell aging related genes can be used to characterize clinical prognoses and further stratify diffuse gliomas.
Yang Y; Chen X; Sun J; Chen S; Yang C; Ma Q; Yang J
Sci Rep; 2021 Sep; 11(1):19493. PubMed ID: 34593910
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
19. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
Wang H; Jiang C
Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
[TBL] [Abstract][Full Text] [Related]
20. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
